Key result
ENGAGE lung cancer trial shows persistent gender imbalance with females comprising only ~32% of enrollees.
There is a persistent gender imbalance in lung cancer clinical trial enrollment, underscoring the need for strategies to ensure equitable access to clinical research.
Warrants caution generalizing lung cancer trial results to women; leaves open best practices for equitable trial enrollment.
was proposed to 167 pts (52%), of whom 13 (4%) were referred to/from other centres.Overall, 154 pts (47.5%) were then enrolled in CT, including observational (72%), interventional (16%) and expanded access programmes (1.3%).Among pts enrolled in CT, 32% were female, 51% were married and 54% had children.54% had a caregiver.Most enrolling oncologists were younger than 45 years, had 10-19 years of experience, worked in research cancer centres and reported fewer than 20 daily pts visits.Reasons for not-considering CT are detailed in the table.Table: 569eP Reasons for not considering CT N of pts (%) Screening failure 7 (2) No trial in those centres 48 (15) No trial in national territory 23 (7) Unsatisfied inclusion/exclusion criteria 38 (11) Patient reluctance 7 (2) Conclusions: ENGAGE is an ongoing multicentre trial providing real-world insights into factors influencing CT enrolment in LC.Preliminary results show a persistent gender imbalance, underscoring the need for strategies to ensure equitable access to clinical research.Clinical trial identification: Protocolv.3.0, released on 30/04/2024.
No takes yet. Share an insight, caveat, or question.
Insolda et al. (2026) studied this question. Lung cancer clinical trial enrollment in the ENGAGE trial demonstrated a persistent gender imbalance, with females comprising only 32% of the 154 enrolled patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: